Danaher
United States
159 articles about Danaher
-
Danaher Reports First Quarter 2024 Results
4/23/2024
Danaher Corporation announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
-
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
2/22/2024
Danaher Corporation announced it has committed to set science-based greenhouse gas emission reduction targets in line with the Science Based Targets initiative, including a long-term target to reach net-zero value chain emissions by no later than 2050.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
Danaher Announces Quarterly Dividend - February 21, 2024
2/21/2024
Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024.
-
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
2/5/2024
Danaher Corporation, a global science and technology innovator, launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials.
-
Danaher Reports Fourth Quarter and Full Year 2023 Results
1/30/2024
Danaher Corporation announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted.
-
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
1/9/2024
Danaher Corporation and the Innovative Genomics Institute launched a collaborative center to develop gene-editing therapies for rare and other diseases, with a goal of creating a new model for future development of a wide range of genomic medicines.
-
Danaher to Present at J.P. Morgan Healthcare Conference - Jan 02, 2024
1/2/2024
Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024 at 2:15 p.m. ET.
-
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
12/21/2023
Danaher Corporation announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.
-
Danaher Completes Acquisition of Abcam
12/6/2023
Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam").
-
Danaher Announces Quarterly Dividend - December 05, 2023
12/5/2023
Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to holders of record on December 29, 2023.
-
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
12/4/2023
Abcam plc, a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation for $24.00 per share in cash, to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006.
-
Social media campaigns may have been one factor that prompted Johnson & Johnson and Danaher to make a TB treatment and a test more accessible in low- and middle-income countries.
-
Shareholders of Abcam Approve Proposed Acquisition by Danaher
11/6/2023
Abcam plc, a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation, announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash.
-
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
10/31/2023
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024.
-
Danaher Reports Third Quarter 2023 Results
10/24/2023
Danaher Corporation announced results for the third quarter ended September 29, 2023.
-
Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam
10/17/2023
Abcam plc, a global leader in the supply of life science research tools, announced that leading independent proxy advisor Institutional Shareholder Services, recommended that Abcam shareholders vote “FOR” Danaher Corporation’s proposed acquisition of Abcam ahead of its shareholder meetings on November 6, 2023.
-
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
10/17/2023
Global genomics solutions provider Integrated DNA Technologies, an operating company in the Life Sciences segment of Danaher Corporation, announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.
-
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
10/5/2023
CAMBRIDGE, England & WALTHAM, Mass.--( BUSINESS WIRE )-- Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today filed and mailed a scheme circular (the 'Scheme Circular‘) in connection with the acquisition of Abcam by Danaher Corporation (NYSE: DHR) (‘Danaher’), announced on August 28, 2023 (the ‘Transaction’). Under the terms of the Transaction Agreement, Danaher will acquire all of the outstanding shares of Abc
-
Danaher Corporation Completes Separation of Veralto Corporation
9/30/2023
Danaher Corporation announced that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation.